Medera Expands Scientific Advisory Board with Leading Heart Failure and Cardiopulmonary Physiology Experts to Advance HFpEF Gene Therapy Program
核心洞察
Medera Inc. (搜索) has appointed three internationally recognized heart failure (搜索) and cardiopulmonary physiology experts — Drs. Gregory Lewis, Marat Fudim, and Rajeev Malhotra — to its Scientific Advisory Board.
The appointments bring deep expertise in cardiac hemodynamics, exercise physiology, and heart failure (搜索) pathophysiology to support the company's HFpEF (搜索) gene therapy program.
Medera's lead candidate, SRD-002, is an AAV-based single-treatment gene therapy designed to restore cardiac calcium handling via targeted intracoronary delivery for HFpEF (搜索) patients.
BOSTON, June 08, 2026 — Medera Inc. (搜索), a clinical-stage biopharmaceutical company developing next-generation disease-modifying cardiovascular therapeutics, today announced the appointment of three internationally recognized leaders in heart failure (搜索) and cardiopulmonary physiology to its Scientific Advisory Board (SAB). The new appointees — Gregory Lewis, MD; Marat Fudim, MD, MHS; and Rajeev Malhotra, MD, MS — bring deep expertise in cardiac hemodynamics, exercise physiology, and heart failure pathophysiology, areas central to Medera's clinical development strategy for heart failure with preserved ejection fraction (HFpEF (搜索)).
"We are very pleased to welcome Drs. Lewis, Fudim, and Malhotra to our Scientific Advisory Board," said Ronald Li, PhD, CEO and Founder of Medera. "As our HFpEF (搜索) program continues to generate consistent and clinically meaningful signals across cardiac hemodynamics and functional measures, the expanded SAB will provide important guidance in further strengthening the clinical and physiological framework supporting the program's next stage of development. We look forward to sharing additional clinical updates in the near term."
Distinguished Expertise Joins the Advisory Board
Gregory Lewis, MD, leads the Heart Failure (搜索) & Transplantation program at Massachusetts General Hospital and directs the Cardiopulmonary Exercise Laboratory. His foundational work has defined mechanisms of exercise intolerance in heart failure, including right ventricular–pulmonary vascular interactions and peripheral oxygen utilization — key drivers of symptoms and functional limitation in HFpEF (搜索). Dr. Lewis holds the Jeffrey & Mary Ellen Jay Endowed Chair in Heart Failure and serves as Professor of Medicine at Harvard Medical School.
Marat Fudim, MD, MHS, heads the Heart Failure (搜索) Unit at Duke University School of Medicine and is a recognized expert in invasive hemodynamics and advanced heart failure management. His clinical and research work focuses on catheter-based assessment and therapeutic strategies to better characterize and treat heart failure physiology.
Rajeev Malhotra, MD, MS, is a leader in cardiopulmonary physiology and cardiovascular translational research at Massachusetts General Hospital and Harvard Medical School. His work integrates human clinical studies with mechanistic insights into vascular biology, metabolism, and cardiac function, supporting the development of novel therapeutic approaches in cardiovascular disease.
SRD-002: A First-in-Human Gene Therapy for HFpEF
Medera is advancing a portfolio of AAV-based cardiac gene therapies targeting fundamental drivers of heart failure (搜索). Its lead program, SRD-002 for HFpEF (搜索), is a single-treatment designed to restore cardiac calcium handling and improve myocardial function. The program utilizes a targeted intracoronary delivery approach designed to enable localized cardiac transduction while minimizing systemic vector exposure.
Clinical data generated to date demonstrate consistent and durable improvements in cardiac hemodynamics and functional measures in HFpEF (搜索) patients, supporting continued advancement toward the next stage of development. In HFpEF, objective physiological endpoints and functional capacity remain key determinants of therapeutic impact — an area where the newly expanded SAB's expertise is particularly relevant.
Strengthened Advisory Leadership
With these appointments, Medera's SAB now represents a highly concentrated group of expertise across heart failure (搜索), cardiopulmonary physiology, and translational cardiovascular science. In addition to Drs. Lewis, Fudim, and Malhotra, the SAB includes Brian Jaski, MD (San Diego Cardiac Center); Hesham Sadek, MD, PhD (University of Arizona College of Medicine); Dongsheng Duan, PhD (University of Missouri School of Medicine); Michael Taylor, MD, PhD (Dell Children's Hospital Medical Center); and Pat Furlong (CEO and Founder of Parent Project Muscular Dystrophy), among others. Collectively, this group has contributed to advancing the understanding of heart failure mechanisms and to shaping the clinical and physiological endpoints used in modern cardiovascular drug development.
Medera operates through two core business units: Novoheart, which provides human-specific cardiac disease modeling and drug discovery platforms, and Sardocor, which leads clinical development of the company's gene therapy pipeline. Together, these capabilities enable a translational approach bridging human-relevant discovery with clinical development.